Travere Therapeutics Inc. (TVTX)

Business: Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases.

IPO Date: 08-Nov-2012

Pres, CEO & Director: Dr. Eric M. Dube Ph.D.

Chief Financial Officer: Ms. Laura M. Clague CPA, CPA

Listing: NASDAQ: TVTX

Country: United States

Headquarters: San Diego, CA

Website: https://www.travere.com

Market cap: $1,567.53 Mln

Revenue (TTM): $228.57 Mln

Earnings (TTM): $-202.20 Mln

Cash: $603.39 Mln

Total Debt: $408.79 Mln

Insider's Holding: 1.44%

Liquidity: Low

52 Week range: $12.75 - 31.65

Shares outstanding: 63,514,200

9 Years Aggregate:

• CFO: $-201.08 Mln
• EBITDA: $-691.64 Mln
• Net Profit: $-881.37 Mln